Molinski Tadeusz F, Dalisay Doralyn S, Lievens Sarah L, Saludes Jonel P
Department of Chemistry and Biochemistry and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, MC 0358, La Jolla, California 92093, USA.
Nat Rev Drug Discov. 2009 Jan;8(1):69-85. doi: 10.1038/nrd2487. Epub 2008 Dec 19.
Drug discovery from marine natural products has enjoyed a renaissance in the past few years. Ziconotide (Prialt; Elan Pharmaceuticals), a peptide originally discovered in a tropical cone snail, was the first marine-derived compound to be approved in the United States in December 2004 for the treatment of pain. Then, in October 2007, trabectedin (Yondelis; PharmaMar) became the first marine anticancer drug to be approved in the European Union. Here, we review the history of drug discovery from marine natural products, and by describing selected examples, we examine the factors that contribute to new discoveries and the difficulties associated with translating marine-derived compounds into clinical trials. Providing an outlook into the future, we also examine the advances that may further expand the promise of drugs from the sea.
在过去几年中，从海洋天然产物中发现药物的研究迎来了复兴。齐考诺肽（普瑞巴林；伊兰制药公司）是一种最初在热带芋螺中发现的肽，它是2004年12月在美国获批用于治疗疼痛的首个海洋来源化合物。随后，在2007年10月，曲贝替定（优得清；法玛西亚公司）成为在欧盟获批的首个海洋抗癌药物。在此，我们回顾从海洋天然产物中发现药物的历史，并通过描述选定的实例，审视促成新发现的因素以及将海洋来源化合物转化为临床试验所面临的困难。展望未来，我们还审视可能进一步拓展海洋药物前景的进展。
